Clinical trial · no report yet · Phase 1
NCT04162015
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
- NCT04162015 ↗
- Active not recruiting
- Memorial Sloan Kettering Cancer Center
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- Nivolumab; Pemetrexed; Cisplatin or Carboplatin
- Arms
- nivolumab with pemetrexed and cisplatin or carboplatin · Experimental
- Enrollment
- 22
- Primary outcomes
- number of patients going to operating room for surgical resection
- Sponsor
- Memorial Sloan Kettering Cancer Center with Bristol-Myers Squibb
- Start
- Nov 12, 2019
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04162015 · updated Sep 11, 2026